IVVD
Invivyd Inc (IVVD)
Healthcare • NASDAQ • $1.50+4.90%
- Symbol
- IVVD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.50
- Daily Change
- +4.90%
- Market Cap
- $424.21M
- Trailing P/E
- N/A
- Forward P/E
- -2.34
- 52W High
- $3.07
- 52W Low
- $0.48
- Analyst Target
- $10.00
- Dividend Yield
- N/A
- Beta
- 0.71
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adim…
Company websiteResearch IVVD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.